*/
Lev Gerlovin, Ezra Josephson | Life Sciences
Let’s say interchangeability is a viable regulatory option for manufacturers of biosimilars. Would it always make sense to seek an interchangeability designation from a strategic perspective? Because of the diversity and complexity of product and manufacturer characteristics, there may not be a single optimal strategy, but rather a continuum. Click below to read the article.
100 days. 14 executive orders. Some bold healthcare policies.
In this CRA Insights, we assess the actions and impact of the second Trump Administration during the first 100 days that directly affect healthcare policy,...